Efficacy Evaluation Of Tigecycline In Treatment Of Severe Pneumonia Caused By Multidrug/Extensively Drug-resistant Acinetobacter Baumannii

Backgroud:Acinetobacter baumannii have acquired resistance and strong ability to communicate cloning, multidrug/extensively drug-resistant Acinetobacter baumannii was the world’s epidemic has become once of the most important pathogen of nosocomial infections, lung was the most commonly infected organ. severe pneumonia caused by multidrug/extensively drug-resistant Acinetobacter baumannii is mainly distributed in ICU, and has high mortality rate,At present for treatment of resistant acinetobacter is lack. As the first glycylcycline was approved to use in clinic, the antibacterial activity of Tigecycline against anticarbapenem resistant Acinetobacter has already been proven in vitro. This study were retrospectively analyzed of the treatments of 160 cases with severe hospital acquired pneumonia caused by MDR/XDR Acinetobacter baumannii in all ICU from November 2011 to August 2014.Objective:To evaluate the clinical efficacy of tigecyline in treatment of severe hospital acquired pneumonia caused by multidrug(MDR)/extensively drug-resistant(XDR) Acinetobacter baumannii.Methods:The treatments of 160 cases with severe hospital acquired pneumonia caused by MDR/XDR Acinetobacter baumannii in all ICU from November 2011 to August 2014 were retrospectively analyzed, among them tigecyline combined with cefoperazone sulbactam were used for 77 patients(group A), compared the rest 83 patients used cefoperazone sulbactam alone(group B) groups.Results:The rates of clinical cure and successful weaning in group A were increased more significantly than in group B after therapy(clinical cure rates:66.23% vs.50.60%, P=0.045; successful weaning rates:62.33% vs.45.78%, P=0.036).28-day mortality in group A was much lower than in group B(22.08% vs.38.55%, P=0.024). Microbiological eradication rates, length of hospital stay, ICU length of stay and adverse reactions among two groups were of no statistically significant difference(all P>0.05).The levels of WBC and CRP after therapy in group A and the level of CRP after therapy in group B were decreased obviously (all P<0.05), and CRP decreased more significantly in group A (P<0.05).Conclusions:Tigecycline combined with cefoperazone sulbactam can achieve good clinical therapeutic effect on severe hospital-acquired pneumonia caused by MDR/XDR Acinetobacter baumannii and is worthy to be promoted in this area.